Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Brindha Rajagopalan"'
Autor:
Meenal Sinha, Courtney Betts, Li Zhang, Madeline J Griffith, Isabelle Solman, Brandon Chen, Eric Liu, Whitney Tamaki, Jacob Stultz, Jaqueline Marquez, Shamilene Sivagnanam, Alexander Cheung, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Matthew Crocker, Kendra Todd, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Charles D Lopez, Margaret Tempero, Lisa M Coussens, Lawrence Fong
Publikováno v:
Journal for immunotherapy of cancer, vol 11, iss 1
BackgroundIn preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine the safety, tolerability, and immunologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2234572939e8210e175f36091a0a956d
https://escholarship.org/uc/item/22n0d044
https://escholarship.org/uc/item/22n0d044
Autor:
Charles D. Lopez, Adel Kardosh, Emerson Yu-sheng Chen, Guillaume Joe Pegna, Alexander Guimaraes, Bryan Foster, Brian Brinkerhoff, Shaun Goodyear, Erin Taber, Brindha Rajagopalan, Johnson Vo, Kiara Siex, Brett Johnson, Danielle Galipeau, Sidney Huszti, Dove Keith, Brett C. Sheppard, Jonathan Brody, Rosalie C. Sears, Gordon B. Mills
Publikováno v:
Journal of Clinical Oncology. 41:TPS781-TPS781
TPS781 Background: Even as the number of targeted agents increases, therapeutic options for PDAC patients remain limited by a lack of biomarkers that can predict the potential clinical benefit of single agents or combination therapeutic strategies. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4dbcacd226a0a1abd2e71d2802c876d
https://doi.org/10.1200/jco.2023.41.4_suppl.tps781
https://doi.org/10.1200/jco.2023.41.4_suppl.tps781
